- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
apoptosis is activated, BAX is not critical for cell death and is recruited only to help the process. If TNFa-mediated cell death plays a significant role in glaucoma related cell death, why, then, is there no cell loss in Bax / mice? One plausible explanation is that secondary degeneration mediated by TNFa release first requires the initial Bax-dependent loss of ganglion cells. This phenomenon will likely be the subject of investigation in the future.
Conclusion
There have been many exciting and important advances in the field of glaucoma research in the last 15 years. As we learn more about the molecular pathways activated in dying ganglion cells, we are beginning to understand many of the complexities of this disease as a whole. More than ever, a comprehensive understanding of initial activating events and subsequent downstream effects will allow future developments of a variety of therapeutic interventions targeted at blocking the progressive loss of neurons associated with this disease.
Abbreviations |
|
Apaf-1 |
apoptosis activating factor-1 |
BH |
Bcl homology |
CytoC |
cytochrome C |
ER |
endoplasmic reticulum |
GCL |
ganglion cell layer |
INL |
inner nuclear layer |
IOP |
intraocular pressure |
JNK |
c-Jun N-terminal kinase |
MA |
membrane anchor |
NMDA |
N-methyl-d-aspartate |
ONL |
outer nuclear layer |
TNF |
tumor necrosis factor |
Acknowledgments
This work was supported by grants from the National Eye Institute (R01 EY12223 to RWN) and an unrestricted research grant from Research
433
to Prevent Blindness, Inc., to the Department of Ophthalmology and Visual Sciences of the University of Wisconsin.
References
Adams, J.M. and Cory, S. (1998) The bcl-2 protein family: arbiters of cell survival. Science, 281: 1322–1326.
Adams, J.A. and Cory, S. (2002) Apoptosomes: engines for caspase activation. Curr. Opin. Cell Biol., 14: 715–720.
Adams, J.M. and Cory, S. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26: 1324–1337.
Anderson, M.G., Smith, R.S., Hawes, N.L., Zabaleta, A., Chang, B., Wiggs, J.L. and John, S.W.M. (2002) Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat. Genet., 30: 81–85.
Bakhshi, A., Jensen, J.P., Goldman, P., Wright, J.J., McBride, O.W., Epstein, A.L. and Korsmeyer, S.J. (1985) Cloning the chromosomal breakpoint of t (14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 41: 899–906.
Berkelaar, M., Clarke, D.B., Wang, Y.-C. and Aguayo, A.J. (1994) Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J. Neurosci., 14: 4368–4374.
Bonfanti, L., Chierzi, S., Cenni, M.C., Strettoi, E., Liu, X.-H., Martinou, J.C., Maffei, L. and Rabacchi, S.A. (1995) Survival of retinal ganglion cells over-expressing Bcl-2 protein in neonatal transgenic mice following optic nerve section. Soc. Neurosci. Abstr., 21: p. 1556.
Bonfanti, L., Strettoi, E., Chierzi, S., Cenni, M.C., Liu, X.-H., Martinou, J.C., Maffei, L. and Rabacchi, S.A. (1996) Protection of retinal ganglion cells from natural and axotomy-induced cell death in neonatal transgenic mice overexpressing bcl-2. J. Neurosci., 16: 4186–4194.
Breckenridge, D.G., Germain, M., Mathai, J.P., Nguyen, M. and Shore, G.C. (2003) Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene, 22: 8608–8618.
Cenni, M.C., Bonfanti, L., Martinou, J.-C., Ratto, G.M., Strettoi, E. and Maffei, L. (1996) Long-term survival of retinal ganglion cells following optic nerve section in adult bcl-2 transgenic mice. Eur. J. Neurosci., 8: 1735–1745.
Chang, B., Smith, R.S., Hawes, N.L., Anderson, M.G., Zabaleta, A., Savinova, O., Roderick, T.H., Heckenlively, J.R., Davisson, M.T. and John, S.W.M. (1999) Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nat. Genet., 21: 405–409.
Chang, L.K., Putcha, G.V., Deshmukh, M. and Johnson, E.M., Jr. (2002) Mitochondrial involvement in the point of no return in neuronal apoptosis. Biochimie, 84: 223–231.
Chaudhary, P., Ahmed, F., Quebada, P. and Sharma, S.C. (1999) Caspase inhibitors block the retinal ganglion cell death following optic nerve transection. Mol. Brain Res., 67: 36–45.
Danial, N.N. and Korsmeyer, S.J. (2004) Cell death: critical control points. Cell, 116: 205–219.
434
Deckwerth, T.L., Elliot, J.L., Knudson, C.M., Johnson, E.M., Jr., Snider, W.D. and Korsmeyer, S.J. (1996) BAX is required for neuronal death after trophic factor deprivation and during development. Neuron, 17: 401–411.
Garcia-Valenzuela, E., Gorczyca, W., Darzynkiewicz, Z. and Sharma, S.C. (1994) Apoptosis in adult retinal ganglion cells after axotomy. J. Neurobiol., 25: 431–438.
Garcia-Valenzuela, E., Shareef, S., Walsh, J. and Sharma, S.C. (1995) Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp. Eye Res., 61: 33–44.
Hekman, M., Albert, S., Galmiche, A., Rennefahrt, U.E.E., Fueller, J., Fischer, A.J., Puehringer, D., Wiese, S. and Rapp, U.R. (2006) Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding. J. Biol. Chem., 281: 17321–17336.
Howell, G.R., Libby, R.T., Jakobs, T.C., Smith, R.S., Phalan, F.C., Barter, J.W., Barbay, J.M., Marchant, J.K., Mahesh, N., Porciatti, V., Whitmore, A.V., Masland, R.H. and John, S.W.M. (2007) Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J. Cell Biol., 179: 1523–1537.
Huang, W., Dobberfuhl, A., Filippopoulos, T., Ingelsson, M., Fileta, J.B., Poulin, N.R. and Grosskreutz, C.L. (2005a) Transcriptional up-regulation and activation of initiating caspases in experimental glaucoma. Am. J. Pathol., 167: 673–681.
Huang, W., Fileta, J.B., Dobberfuhl, A., Filippopoulos, T., Guo, Y., Kwon, G. and Grosskreutz, C.L. (2005b) Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc. Natl. Acad. Sci. U.S.A., 102: 12242–12247.
Isenmann, S., Wahl, C., Krajewski, S., Reed, J.C. and Ba¨hr, M. (1997) Up-regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat. Eur. J. Neurosci., 9: 1763–1772.
John, S.W.M., Smith, R.S., Savinova, O.V., Hawes, N.L., Chang, B., Turnbull, D., Davisson, M., Roderick, T.H. and Heckenlively, J.R. (1998) Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest. Ophthalmol. Vis. Sci., 39: 951–962.
Kaufmann, T., Schlipf, S., Sanz, J., Neubert, K., Stein, R. and Borner, C. (2003) Characterization of the signal that directs Bcl-XL, but not Bcl-2, to the mitochondrial outer membrane. J. Cell Biol., 160: 53–64.
Kermer, P., Ankerhold, R., Klocker, N., Krajewski, S., Reed, J.C. and Ba¨hr, M. (2000) Caspase-9 involvement in secondary death of axotomized rat retinal ganglion cells in vivo. Brain Res. Mol. Brain Res., 28: 144–150.
Kermer, P., Klo¨cker, N., Labes, M. and Ba¨hr, M. (1998) Inhibition of CPP32-like proteases rescues axotomized retinal ganglion cells from secondary death in vivo. J. Neurosci., 18: 4656–4662.
Kerrigan, L.A., Zack, D.J., Quigley, H.A., Smith, S.D. and Pease, M.E. (1997) TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol., 115: 1031–1035.
Kretz, A., Ku¨gler, S., Happold, C., Ba¨hr, M. and Isenmann, S. (2004) Excess BclXL increases the intrinsic growth potential of adult CNS neurons in vitro. Mol. Cell Neurosci., 26: 63–74.
Kwong, J.M. and Caprioli, J. (2006) Expression of phosphorylated c-Jun N-terminal kinase (JNK) in experimental glaucoma in rats. Exp. Eye Res., 82: 576–582.
Levin, L.A. and Louhab, A. (1996) Apoptosis of retinal ganglion cells in anterior ischemic optic neuropathy. Arch. Ophthalmol., 114: 488–491.
Levin, L.A., Schlamp, C.L., Spieldoch, R.L., Geszvain, K.M. and Nickells, R.W. (1997) Identification of bcl-2 family genes in the rat retina. Invest. Ophthalmol. Vis. Sci., 38: 2545–2553.
Levkovitch-Verbin, H., Harizman, N., Dardik, R., Nisgav, Y., Vander, S. and Melamed, S. (2007) Regulation of cell death and survival pathways in experimental glaucoma. Exp. Eye Res., 85: 250–258.
Li, Y., Schlamp, C.L. and Nickells, R.W. (1999) Experimental induction of retinal ganglion cell death in adult mice. Invest. Ophthalmol. Vis. Sci., 40: 1004–1008.
Li, Y., Schlamp, C.L., Poulsen, K.P. and Nickells, R.W. (2000) Bax-dependent and independent pathways of retinal ganglion cell death induced by different damaging stimuli. Exp. Eye Res., 71: 209–213.
Libby, R.T., Anderson, M.G., Pang, I.-H., Robinson, Z.H., Savinova, O.V., Cosma, I.M., Snow, A., Wilson, L.A., Smith, R.S., Clark, A.F. and John, S.W.M. (2005a) Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration. Vis. Neurosci., 22: 637–648.
Libby, R.T., Li, Y., Savinova, O.V., Barter, J., Smith, R.S., Nickells, R.W. and John, S.W.M. (2005b) Susceptibility to neurodegeneration in glaucoma is modified by Bax gene dosage. PLoS Genet., 1: 17–26.
Liu, X., Zhu, Y., Dai, S., White, J., Peyerl, F., Kappler, J.W. and Marrack, P. (2006) Bcl-XL does not have to bind to Bax to protect T cells from death. J. Exp. Med., 203: 2953–2961.
Liu, X.H., Collier, R.J. and Youle, R.J. (2001) Inhibition of axotomy-induced neuronal apoptosis by extracellular delivery of a Bcl-XL fusion protein. J. Biol. Chem., 276: 46326–46332.
Malik, J.M.I., Shevtsova, Z., Bahr, M. and Kugler, S. (2005) Long-term in vivo inhibition of CNS neurodegeneration by BclXL gene transfer. Mol. Ther., 11: 373–381.
McKernan, D.P. and Cotter, T.G. (2007) A critical role for Bim in retinal ganglion cell death. J. Neurochem., 102: 922–930.
McKinnon, S.J., Lenhman, D.M., Kerrigan-Baumrind, L.A., Merges, C.A., Pease, M.E., Kerrigan, D.F., Ransom, N.L., Tahzib, N.G., Reitsamer, H.A., Levkovitch-Verbin, H., Quigley, H.A. and Zack, D.J. (2002) Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci., 43: 1077–1087.
Misantone, L.J., Gershenbaum, M. and Murray, M. (1984) Viability of retinal ganglion cells after optic nerve crush in rats. J. Neurocytol., 13: 449–465.
Mittag, T.W., Danias, J., Pohorenec, G., Yuan, H.M., Burakgazi, E., Chalmers-Redman, R., Podos, S.M. and Tatton, W.G. (2000) Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci., 41: 3451–3459.
Mo, J.S., Anderson, M.G., Gregory, M., Smith, R.S., Savinova, O.V., Sereze, D.V., Ksander, B.R., Streilein, J.W. and John, S.W.M. (2003) By altering ocular immune privilege, bone marrow-derived cells pathogenetically contribute to DBA/2J pigmentary glaucoma. J. Exp. Med., 197: 1335–1344.
Morgan, J.E. (2002) Retinal ganglion cell shrinkage in glaucoma. J. Glaucoma, 11: 365–370.
Morgan, J.E., Uchida, H. and Caprioli, J. (2000) Retinal ganglion cell death in experimental glaucoma. Br. J. Ophthalmol., 84: 303–310.
Mosinger Ogilvie, J., Deckwerth, T.L., Knudson, C.M. and Korsmeyer, S.J. (1998) Suppression of developmental retinal cell death but not photoreceptor degeneration in Baxdeficient mice. Invest. Ophthalmol. Vis. Sci., 39: 1713–1720.
Nakazawa, T., Nakazawa, C., Matsubara, A., Noda, K., Hisatomi, T., She, H., Michaud, N., Hafezi-Moghadam, A., Miller, J.W. and Benowitz, L.I. (2006) Tumor necrosis factor- a mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J. Neurosci., 26: 12633–12641.
Nickells, R.W. (2004) The molecular biology of retinal ganglion cell death: caveats and controversies. Brain Res. Bull., 62: 439–446.
Nickells, R.W. (2007) From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can. J. Ophthalmol., 42: 278–287.
Nutt, L.K., Chandra, J., Pataer, A., Fang, B., Roth, J.A., Swisher, S.G., O’Neil, R.G. and McConkey, D.J. (2002) Baxmediated Ca2+ mobilizatoin promotes cytochrome C release during apoptosis. J. Biol. Chem., 277: 20301–20308.
Na¨pa¨nkangas, U., Lindqvist, N., Lindholm, D. and Hallbo¨o¨k, F. (2003) Rat retinal ganglion cells upregulate the proapoptotic BH3-only protein Bim after optic nerve transection. Mol. Brain Res., 120: 30–37.
Polster, B.M. and Fiskum, G. (2004) Mitochondrial mechanisms of neuronal cell apoptosis. J. Neurochem., 90: 1281–1289.
Putcha, G.V., Deshmukh, M. and Johnson, E.M., Jr. (1999) BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, BCL-2, and caspases. J. Neurosci., 19: 7476–7485.
Putcha, G.V., Le, S., Frank, S., Besirli, C.G., Clark, K., Chu, B., Alix, S., Youle, R.J., LaMarche, A., Maroney, A.C. and Johnson, E.M., Jr. (2003) JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron, 38: 899–914.
Quigley, H.A., Addicks, E.M., Green, W.R. and Maumenee, A.E. (1981) Optic nerve damage in human glaucoma: II. The site of injury and susceptibility to damage. Arch. Ophthalmol., 99: 635–649.
Quigley, H.A., Nickells, R.W., Kerrigan, L.A., Pease, M.E., Thibault, D.J. and Zack, D.J. (1995) Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci., 36: 774–786.
Salvesen, G.S. and Dixit, V.M. (1997) Caspases: intracellular signaling by proteolysis. Cell, 91: 443–446.
435
Schlamp, C.L., Li, Y., Dietz, J.A., Janssen, K.T. and Nickells, R.W. (2006) Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci., 7: p. 66.
Schwartz, M. (2005) Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all?. J. Glaucoma, 14: 321–323.
Slee, E.A., Harte, M.T., Kluck, R.M., Wolf, B.B., Casiano, C.A., Newmeyer, D.D., Wang, H.-G., Reed, J.C., Nicholson, D.W., Alnemri, E.S., Green, D.R. and Martin, S.J. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol., 144: 281–292.
Tatton, W.G., Chalmers-Redman, R.M., Sud, A., Podos, S.M. and Mittag, T.W. (2001) Maintaining mitochondrial membrane impermeability: an opportunity for new therapy in glaucoma?. Surv. Ophthalmol., 45(suppl.): S295–S296.
Tezel, G. (2006) Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res., 25: 490–513.
Tezel, G. and Wax, M.B. (2000) Increased production of tumor necrosis factor-a by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J. Neurosci., 20: 8693–8700.
Tezel, G., Li, L.Y., Patil, R.V. and Wax, M.B. (2001) TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest. Ophthalmol. Vis. Sci., 42: 1787–1794.
Tezel, G., Yang, X., Yang, J. and Wax, M.B. (2004) Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res., 996: 202–212.
Weber, A.J., Kaufman, P.L. and Hubbard, W.C. (1998) Morphology of single ganglion cells in the glaucomatous primate retina. Invest. Ophthalmol. Vis. Sci., 39: 2304–2320.
Wei, M.C., Zong, W.X., Cheng, E.H.Y., Lindsten, T., Panoutsakopoulou, V., Ross, A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B. and Korsmeyer, S.J. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 292: 727–730.
Weinreb, R.N. and Lindsey, J.D. (2005) The importance of models in glaucoma research. J. Glaucoma, 14: 302–304.
White, F.A., Keller-Peck, C.R., Knudson, C.M., Korsmeyer, S.J. and Snider, W.D. (1998) Widespread elimination of naturally occurring neuronal death in bax-deficient mice. J. Neurosci., 18: 1428–1439.
Whitmore, A.V., Libby, R.T. and John, S.W.M. (2005) Glaucoma: thinking in new ways — a role for autonomous axonal self-destruction and compartmentalised processes? Prog. Retin. Eye Res., 24: 639–662.
Wolter, K.G., Hsu, Y.T., Smith, C.L., Nechushtan, A., Xi, X.G. and Youle, R.J. (1997) Movement of bax from the cytosol to mitochondria during apoptosis. J. Cell Biol., 139: 1281–1292.